22534 Federal Register / Vol. 87, No. 73 / Friday, April 15, 2022 / Notices 

5. How can AHRQ have the greatest 

impact and success at achieving the 

vision and mission of the strategic 

framework? 

a. What is the most effective way to 

ensure the sustainability of initiatives 

that seek to enhance the integration of 

patient-centered outcomes research 

findings into practice? 

b. What complementary partnerships 

and collaborations (both public and 

private) would increase the impact of 

AHRQ’s PCORTF investments? 

c. What will be the best way of 

measuring progress and the overall 

impact of AHRQ’s PCORTF 

investments? 

6. Is there anything else you would 

like to share regarding the strategic 

framework? 

AHRQ is interested in all of the 

questions listed above, but respondents 

are welcome to address as many or as 

few as they choose and to address 

additional areas of interest not listed. It 

is helpful to identify which question a 

particular answer is a response to. 

This RFI is for planning purposes 

only and should not be construed as a 

policy, solicitation for applications, or 

as an obligation on the part of the 

Government to provide support for any 

ideas identified in response to it. AHRQ 

will use the information submitted in 

response to this RFI at its discretion and 

will not provide comments to any 

responder’s submission. However, 

responses to the RFI may be reflected in 

future solicitation(s) or policies. The 

information provided will be analyzed 

and may appear in reports. Respondents 

will not be identified in any published 

reports. Respondents are advised that 

the Government is under no obligation 

to acknowledge receipt of the 

information received or provide 

feedback to respondents with respect to 

any information submitted. No 

proprietary, classified, confidential, or 

sensitive information should be 

included in your response. The contents 

of all submissions will be made 

available to the public upon request. 

Materials submitted must be publicly 

available or able to be made public. 

Dated: April 11, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–08038 Filed 4–14–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–OH–20–002, Commercial Fishing 

Occupational Safety Research 

Cooperative Agreement; and RFA–OH– 

20–003, Commercial Fishing 

Occupational Safety Training Project 

Grants. 

Date: May 18, 2022. 

Time: 12:00 p.m.–3:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, CDC, 

1095 Willowdale Road, Morgantown, 

West Virginia 26505, Telephone: (304) 

285–5951; Email: MGoldcamp@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–08051 Filed 4–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3423–N] 

Announcement of the Re-Approval of 

the American Society of 

Histocompatibility and 

Immunogenetics (ASHI) as an 

Accreditation Organization Under the 

Clinical Laboratory Improvement 

Amendments of 1988 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

application of the American Society for 

Histocompatibility and Immunogenetics 

(ASHI) for approval as an accreditation 

organization for clinical laboratories 

under the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) program for the following 

specialty and subspecialty areas: 

General Immunology; 

Histocompatibility; and ABO/Rh typing. 

We have determined that the ASHI 

meets or exceeds the applicable CLIA 

requirements. In this notice, we 

announce the approval and grant the 

ASHI deeming authority for a period of 

6 years. 

DATES: This notice is effective from 

April 15, 2022 to April 15, 2028. 

FOR FURTHER INFORMATION CONTACT: 

Penny Keller, (410) 786–2035. 

SUPPLEMENTARY INFORMATION: 

I. Background and Legislative 

Authority 

On October 31, 1988, the Congress 

enacted the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) (Pub. L. 100–578). CLIA 

amended section 353 of the Public 

Health Service Act. We issued a final 

rule implementing the accreditation 

provisions of CLIA on July 31, 1992 (57 

FR 33992). Under those provisions, 

CMS may grant deeming authority to an 

accreditation organization if its 

requirements for laboratories accredited 

under its program are equal to or more 

stringent than the applicable CLIA 

program requirements in 42 CFR part 

493 (Laboratory Requirements). Subpart 

E of part 493 (Accreditation by a Private, 

Nonprofit Accreditation Organization or 

Exemption Under an Approved State 

Laboratory Program) specifies the 

requirements an accreditation 

organization must meet to be approved 

by CMS as an accreditation organization 

under CLIA. 


jspears on DSK121TN23PROD with NOTICES1